Sanofi’s immunology bet starts to pay off
Bio Pharma Dive
JULY 25, 2024
Some analysts described Sanofi’s pipeline of immune system therapies, which includes more than half a dozen drugs in mid- to late-stage testing, as “underappreciated” by investors, as sales of Dupixent rose over the last quarter.
Let's personalize your content